Senseonics (NYSE:SENS) Shares Gap Down – Here’s What Happened

Senseonics Holdings, Inc. (NYSE:SENS) shares gapped down prior to trading on Monday . The stock had previously closed at $0.96, but opened at $0.84. Senseonics shares last traded at $0.90, with a volume of 5,892,521 shares.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SENS shares. StockNews.com started coverage on Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Trading Down 6.2 %

The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.44. The company has a market cap of $536.39 million, a PE ratio of -6.95 and a beta of 0.69.

Senseonics (NYSE:SENS) last released its earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $4.26 million for the quarter, compared to analysts’ expectations of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. Sell-side analysts forecast that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Insider Activity at Senseonics

In related news, CFO Frederick T. Sullivan bought 124,933 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the transaction, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Large investors have recently modified their holdings of the company. Symmetry Partners LLC bought a new position in Senseonics in the 3rd quarter worth $164,000. GSA Capital Partners LLP acquired a new stake in shares of Senseonics in the third quarter valued at about $117,000. Geode Capital Management LLC increased its stake in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares during the period. FMR LLC lifted its position in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the last quarter. Finally, Ridgecrest Wealth Partners LLC bought a new stake in Senseonics during the 4th quarter valued at approximately $60,000. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.